Pub Date : 2023-09-01DOI: 10.1097/01.ogx.0000979680.95107.1b
Jilcha D. Feyisa, Mathewos A. Woldegeorgis, Girum T. Zingeta, Kedir H. Abegaz, Yemane Berhane
ABSTRACT Nonmetastatic cervical cancer is a highly curable malignancy, and radiotherapy (RT) remains the mainstay treatment. Early initiation is critical, and the optimal time to initiate RT for cure is 6 weeks, with a reported 15% decrease in 3-year overall survival for those who wait 40 days. There is considerable variation in the waiting time to initiate RT between countries, with a median time of 27.2 days in Ontario, Canada and 108 days in South Africa. Real-world evidence of cancer progression because of treatment delay is scarce in low-income countries. Ethiopia, a country of 120 million, had a single machine at Tikur Anbessa Specialized Hospital (TASH) until it acquired a linear accelerator very recently. This study aimed to assess the extent of delay in receiving RT and the effect of delay on the natural disease court in patients with cervical cancer treated at TASH. This study was conducted at TASH between January 2019 and May 2020 and evaluated patients at different time points before and after RT. All individuals who were diagnosed with cervical cancer (stage IIB to stage IVA) and booked for RT at TASH were included. Concurrent chemoradiotherapy was administered for cervical cancer with weekly cisplatin as a chemotherapy agent. A total of 115 patients were included in this study. The median time between pathologic diagnosis and booking RT was 19 days, and the median time from booking to RT initiation was 458 days. The total median time from diagnosis to treatment was 477 days, and the median time to disease progression was 51 days. During the waiting period for RT, the stage was reassessed for 105 patients. The number of patients in stage IIB, IIA, and IIIB decreased during this period, whereas the number of patients in stage IVA increased from 20 (17.4%) to 30 (26.1%), 2 (1.8%) developed distant metastasis to the lungs (stage IVB), and 37 died before receiving a phone call for RT. Of 115 patients booked to receive CCRT, only 9 (7.8%) received CCRT, 80 (69.9%) received a single shot of palliative RT due to disease progression, and 25 (21.7%) did not receive RT at all. The mean and median survival times were 20.1 months (95% confidence interval [CI], 18.3–22.7) and 21 months (95% CI, 18.3–23.8), respectively. Waiting time, stage at presentation, distant metastasis during the waiting time, hydronephrosis during the waiting time, and type of treatment were significantly associated with survival. Multivariate cox regression using these variables found that patients with stage IIIB were 2.2 times more likely to die than those with stage IIB (adjusted hazards ratio, 2.2; 95% CI, 1.07–4.48), and patients with stage IVA were 20.95 times more likely to die than patients with stage IIB (adjusted hazards ratio, 20.95; 95% CI, 6.26–70.03). Prolonged waiting time increased the mortality rate of cervical cancer by 2.9 (95% CI, 1.07–4.5). This study provides a significant advancement in our understanding of cervical cancer care in low-income countri
{"title":"Cervical Cancer Progression in Patients Waiting for Radiotherapy Treatment at a Referral Center in Ethiopia: A Longitudinal Study","authors":"Jilcha D. Feyisa, Mathewos A. Woldegeorgis, Girum T. Zingeta, Kedir H. Abegaz, Yemane Berhane","doi":"10.1097/01.ogx.0000979680.95107.1b","DOIUrl":"https://doi.org/10.1097/01.ogx.0000979680.95107.1b","url":null,"abstract":"ABSTRACT Nonmetastatic cervical cancer is a highly curable malignancy, and radiotherapy (RT) remains the mainstay treatment. Early initiation is critical, and the optimal time to initiate RT for cure is 6 weeks, with a reported 15% decrease in 3-year overall survival for those who wait 40 days. There is considerable variation in the waiting time to initiate RT between countries, with a median time of 27.2 days in Ontario, Canada and 108 days in South Africa. Real-world evidence of cancer progression because of treatment delay is scarce in low-income countries. Ethiopia, a country of 120 million, had a single machine at Tikur Anbessa Specialized Hospital (TASH) until it acquired a linear accelerator very recently. This study aimed to assess the extent of delay in receiving RT and the effect of delay on the natural disease court in patients with cervical cancer treated at TASH. This study was conducted at TASH between January 2019 and May 2020 and evaluated patients at different time points before and after RT. All individuals who were diagnosed with cervical cancer (stage IIB to stage IVA) and booked for RT at TASH were included. Concurrent chemoradiotherapy was administered for cervical cancer with weekly cisplatin as a chemotherapy agent. A total of 115 patients were included in this study. The median time between pathologic diagnosis and booking RT was 19 days, and the median time from booking to RT initiation was 458 days. The total median time from diagnosis to treatment was 477 days, and the median time to disease progression was 51 days. During the waiting period for RT, the stage was reassessed for 105 patients. The number of patients in stage IIB, IIA, and IIIB decreased during this period, whereas the number of patients in stage IVA increased from 20 (17.4%) to 30 (26.1%), 2 (1.8%) developed distant metastasis to the lungs (stage IVB), and 37 died before receiving a phone call for RT. Of 115 patients booked to receive CCRT, only 9 (7.8%) received CCRT, 80 (69.9%) received a single shot of palliative RT due to disease progression, and 25 (21.7%) did not receive RT at all. The mean and median survival times were 20.1 months (95% confidence interval [CI], 18.3–22.7) and 21 months (95% CI, 18.3–23.8), respectively. Waiting time, stage at presentation, distant metastasis during the waiting time, hydronephrosis during the waiting time, and type of treatment were significantly associated with survival. Multivariate cox regression using these variables found that patients with stage IIIB were 2.2 times more likely to die than those with stage IIB (adjusted hazards ratio, 2.2; 95% CI, 1.07–4.48), and patients with stage IVA were 20.95 times more likely to die than patients with stage IIB (adjusted hazards ratio, 20.95; 95% CI, 6.26–70.03). Prolonged waiting time increased the mortality rate of cervical cancer by 2.9 (95% CI, 1.07–4.5). This study provides a significant advancement in our understanding of cervical cancer care in low-income countri","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/01.ogx.0000979676.12813.5a
Emily Heer, Cheryl Peters, Rod Knight, Lin Yang, Steven J. Heitman
ABSTRACT Compared with cisgender and heterosexual individuals, members of the LGBTQ+ community experience worse health outcomes. This is due to a combination of structural inequities and life experiences, including higher rates of mental illness and suicidality, sexually transmitted infections, and certain cancers. Men who have sex with men are at higher risk of anal cancer, and lesbian and bisexual women are often diagnosed with breast cancer at younger ages than heterosexual women partly due to lower parity and higher bodyweight. Despite these increased risks, some evidence shows the LGBTQ+ population is less likely to participate in early detection and cancer screening programs; however, the etiology of this is unknown. This review aims to summarize the current literature on cancer screening uptake in the LGBTQ+ population, including barriers and facilitators associated with screening participation. Studies published between January 2001 and April 2022 involving individuals identified as a gender or sexual minority that assessed participation in and/or facilitators and barriers to a cancer screening procedure were included. Barriers and facilitators identified in quantitative studies were reported on the individual-, provider-, and administrative/system-level scale. A total of 50 publications were included, 38 of which were quantitative, 10 were qualitative, and 2 used mixed methods. Among 16 relevant studies, considerable variation was identified when analyzing whether sexual minority women had lower participation in cervical cancer screening programs. Among 15 studies assessing the participation of sexual minority women compared with heterosexual women in breast cancer screening, 5 studies found no difference, whereas the remainder suggested lower rates of screening among sexual minority women. Fewer studies assessed screening among sexual minority men; however, sexual minority men were more likely to report anal cancer screening than heterosexual men. Cervical cancer screening participation among transgender men and gender diverse participants was lower than cisgender participants in almost all studies. Of 9 studies reporting breast cancer screening among gender diverse or transgender individuals, 5 found lower participation among transgender or gender diverse individuals compared with cisgender women. One study identified greater odds of up-to-date mammography among transgender men compared with cisgender women. The most common individual-level barriers to screening are related to knowledge of the screening tests themselves, including screening guidelines, procedures, pain, embarrassment, and a fear of results. One of the strongest correlates in studies was perceived discrimination from health care providers, which often resulted in lack of disclosure of sexual orientation or gender identity. Provider-level factors mostly included provider communication and relationship with the patient, and patients preferred providers experienced with LG
{"title":"Participation, Barriers, and Facilitators of Cancer Screening Among LGBTQ+ Populations: A Review of the Literature","authors":"Emily Heer, Cheryl Peters, Rod Knight, Lin Yang, Steven J. Heitman","doi":"10.1097/01.ogx.0000979676.12813.5a","DOIUrl":"https://doi.org/10.1097/01.ogx.0000979676.12813.5a","url":null,"abstract":"ABSTRACT Compared with cisgender and heterosexual individuals, members of the LGBTQ+ community experience worse health outcomes. This is due to a combination of structural inequities and life experiences, including higher rates of mental illness and suicidality, sexually transmitted infections, and certain cancers. Men who have sex with men are at higher risk of anal cancer, and lesbian and bisexual women are often diagnosed with breast cancer at younger ages than heterosexual women partly due to lower parity and higher bodyweight. Despite these increased risks, some evidence shows the LGBTQ+ population is less likely to participate in early detection and cancer screening programs; however, the etiology of this is unknown. This review aims to summarize the current literature on cancer screening uptake in the LGBTQ+ population, including barriers and facilitators associated with screening participation. Studies published between January 2001 and April 2022 involving individuals identified as a gender or sexual minority that assessed participation in and/or facilitators and barriers to a cancer screening procedure were included. Barriers and facilitators identified in quantitative studies were reported on the individual-, provider-, and administrative/system-level scale. A total of 50 publications were included, 38 of which were quantitative, 10 were qualitative, and 2 used mixed methods. Among 16 relevant studies, considerable variation was identified when analyzing whether sexual minority women had lower participation in cervical cancer screening programs. Among 15 studies assessing the participation of sexual minority women compared with heterosexual women in breast cancer screening, 5 studies found no difference, whereas the remainder suggested lower rates of screening among sexual minority women. Fewer studies assessed screening among sexual minority men; however, sexual minority men were more likely to report anal cancer screening than heterosexual men. Cervical cancer screening participation among transgender men and gender diverse participants was lower than cisgender participants in almost all studies. Of 9 studies reporting breast cancer screening among gender diverse or transgender individuals, 5 found lower participation among transgender or gender diverse individuals compared with cisgender women. One study identified greater odds of up-to-date mammography among transgender men compared with cisgender women. The most common individual-level barriers to screening are related to knowledge of the screening tests themselves, including screening guidelines, procedures, pain, embarrassment, and a fear of results. One of the strongest correlates in studies was perceived discrimination from health care providers, which often resulted in lack of disclosure of sexual orientation or gender identity. Provider-level factors mostly included provider communication and relationship with the patient, and patients preferred providers experienced with LG","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/01.ogx.0000979664.42491.de
M. Pagan, E. F. Magann, N. Rabie, S. C. Steelman, Z. Hu, S. Ounpraseuth
ABSTRACT Amniotic fluid volume (AFV) is examined via ultrasound often several times in pregnancy and can be an indicator of the overall health of a fetus. However, disorders of amniotic fluid can arise without complications for the fetus; excess of amniotic fluid without any accompanying fetal conditions is referred to as idiopathic polyhydramnios. Previous research has shown conflicting results with regard to outcomes related to idiopathic polyhydramnios, with some finding it increases adverse outcomes and others reporting an increase in adverse outcomes only in moderate or severe cases. This study is a systematic review and meta-analysis meant to assess the relationship between idiopathic polyhydramnios and perinatal outcomes for singleton pregnancies. Eligibility criteria included studies that had a control group with normal AFV and defined polyhydramnios as an amniotic fluid index of 24 cm or greater or a single deepest pocket of 8 cm or greater. Similar methods of defining polyhydramnios were considered as long as they were evidence-based. Studies with known causes of polyhydramnios were excluded to ensure cases analyzed for this study were idiopathic. The primary outcome was intrauterine fetal demise, with secondary outcomes of neonatal death, neonatal intensive care unit (NICU) admission, macrosomia, 5-minute Apgar score, malpresentation, and cesarean delivery. Final review and analysis included 12 articles, with a total of 2392 patients with idiopathic polyhydramnios and 160,135 patients with normal AFV. Risk of bias was determined to be low for these studies, although the comparability was not well-defined. Analysis for the primary outcome included 8 of the 12 studies and showed that the risk of intrauterine fetal demise was increased in those with idiopathic polyhydramnios (odds ratio [OR], 7.64; 95% confidence interval [CI], 2.50–23.38). Secondary outcome analysis for neonatal death showed that individuals with polyhydramnios were 8.68 times more likely to experience neonatal death than controls (95% CI, 2.91–25.87). Examining other secondary outcomes, the association between NICU admission and idiopathic polyhydramnios showed that patients with polyhydramnios were more likely to be admitted to the NICU (OR, 1.94; 95% CI, 1.45 – 2.59). When assessing 5-minute Apgar scores, results showed that individuals with polyhydramnios were more likely to have an Apgar score of less than 7 (OR, 2.21; 95% CI, 1.34–3.62). In addition, rates of cesarean delivery were significantly higher with idiopathic polyhydramnios (OR, 2.31; 95% CI, 1.79–2.99), as was macrosomia (OR, 2.93; 95% CI, 2.39–3.59). Malpresentation was also higher in the polyhydramnios group than in the control group (OR, 2.73; 95% CI, 2.06–3.61). The authors of this meta-analysis conclude that in pregnancies with idiopathic polyhydramnios, there is an elevated risk of both intrauterine fetal demise and neonatal death. In addition, all other negative pregnancy outcomes analyzed were mor
{"title":"Idiopathic Polyhydramnios and Pregnancy Outcome: Systematic Review and Meta-analysis","authors":"M. Pagan, E. F. Magann, N. Rabie, S. C. Steelman, Z. Hu, S. Ounpraseuth","doi":"10.1097/01.ogx.0000979664.42491.de","DOIUrl":"https://doi.org/10.1097/01.ogx.0000979664.42491.de","url":null,"abstract":"ABSTRACT Amniotic fluid volume (AFV) is examined via ultrasound often several times in pregnancy and can be an indicator of the overall health of a fetus. However, disorders of amniotic fluid can arise without complications for the fetus; excess of amniotic fluid without any accompanying fetal conditions is referred to as idiopathic polyhydramnios. Previous research has shown conflicting results with regard to outcomes related to idiopathic polyhydramnios, with some finding it increases adverse outcomes and others reporting an increase in adverse outcomes only in moderate or severe cases. This study is a systematic review and meta-analysis meant to assess the relationship between idiopathic polyhydramnios and perinatal outcomes for singleton pregnancies. Eligibility criteria included studies that had a control group with normal AFV and defined polyhydramnios as an amniotic fluid index of 24 cm or greater or a single deepest pocket of 8 cm or greater. Similar methods of defining polyhydramnios were considered as long as they were evidence-based. Studies with known causes of polyhydramnios were excluded to ensure cases analyzed for this study were idiopathic. The primary outcome was intrauterine fetal demise, with secondary outcomes of neonatal death, neonatal intensive care unit (NICU) admission, macrosomia, 5-minute Apgar score, malpresentation, and cesarean delivery. Final review and analysis included 12 articles, with a total of 2392 patients with idiopathic polyhydramnios and 160,135 patients with normal AFV. Risk of bias was determined to be low for these studies, although the comparability was not well-defined. Analysis for the primary outcome included 8 of the 12 studies and showed that the risk of intrauterine fetal demise was increased in those with idiopathic polyhydramnios (odds ratio [OR], 7.64; 95% confidence interval [CI], 2.50–23.38). Secondary outcome analysis for neonatal death showed that individuals with polyhydramnios were 8.68 times more likely to experience neonatal death than controls (95% CI, 2.91–25.87). Examining other secondary outcomes, the association between NICU admission and idiopathic polyhydramnios showed that patients with polyhydramnios were more likely to be admitted to the NICU (OR, 1.94; 95% CI, 1.45 – 2.59). When assessing 5-minute Apgar scores, results showed that individuals with polyhydramnios were more likely to have an Apgar score of less than 7 (OR, 2.21; 95% CI, 1.34–3.62). In addition, rates of cesarean delivery were significantly higher with idiopathic polyhydramnios (OR, 2.31; 95% CI, 1.79–2.99), as was macrosomia (OR, 2.93; 95% CI, 2.39–3.59). Malpresentation was also higher in the polyhydramnios group than in the control group (OR, 2.73; 95% CI, 2.06–3.61). The authors of this meta-analysis conclude that in pregnancies with idiopathic polyhydramnios, there is an elevated risk of both intrauterine fetal demise and neonatal death. In addition, all other negative pregnancy outcomes analyzed were mor","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/ogx.0000000000001196
Jinlin Xie, Na Li, Haiyan Bai, Juanzi Shi, He Cai
ABSTRACT The prevalence of obesity in reproductive age women continues to increase worldwide. Recent meta-analyses suggest that female obesity is negatively associated with live birth rate (LBR) after in vitro fertilization, as well as a higher risk of miscarriage after euploid embryo transfer. The interplay between adiposity and reproductive hormones such as progesterone may be partially responsible, and research shows that obese women may require higher progesterone supplementation in frozen-thawed embryo transfer (FET). Although the vaginal route of progesterone supplementation has predominated in most in vitro fertilization centers globally, the route of supplementation has been gaining interest. Studies comparing different routes have focused on the general infertility population, and it remains essential to investigate the interrelationship between the routes of progesterone supplementation, overweight/obesity, and treatment outcomes. This retrospective cohort study aimed to compare the difference in the LBR between vaginal progesterone and intramuscular progesterone in cryopreserved blastocyst transfer cycles and assess whether obesity may modify these associations. Patients who underwent a single, vitrified-warmed, blastocyst transfer between January 2018 and June 2021 and received exogenous hormone replacement for endometrial preparation were included. The route of progesterone supplementation was based on patient preference. The primary study outcome was live birth, and secondary outcomes included a positive b-hCG test result, clinical pregnancy, miscarriage, and total pregnancy loss. Normal weight was defined as 18.5–24.9 kg/m 2 , overweight was defined as a body mass index (BMI) of 25–29 kg/m 2 , and obese was defined as ≥30 kg/m 2 . Multivariate regression was used to assess the association between the route of progesterone supplementation and LBR while controlling for known potential covariates, and an interaction analysis was performed with overweight/obesity as the interaction term. A total of 6905 FET cycles from 6251 patients were included for this analysis, with 4616 cycles using vaginal progesterone and 2289 cycles using intramuscular progesterone. The proportions of overweight and obese women were comparable between the 2 groups. After adjusting for confounding variables, the LBR in the vaginal and intramuscular progesterone groups were 46.23% (2134/4616) and 48.62% (1113/2289), respectively (adjusted odds ratio [aOR], 0.89; 95% confidence interval [CI], 0.81–0.98). Although the rates of a positive serum hCG result and clinical pregnancy were similar between the 2 groups, miscarriage rate (15.34% vs 11.40%; aOR, 1.40; 95% CI, 1.20–1.63) and total pregnancy loss (22.22% vs 18.90%; aOR, 1.23; 95% CI, 1.08–1.40) per FET were significantly higher in the vaginal progesterone group than in the intramuscular progesterone group. Among normal-weight women, the LBR was lower in the vaginal progesterone group than the intramuscular prog
{"title":"Overweight and Obesity Affect The Efficacy of Vaginal vs. Intramuscular Progesterone for Luteal-Phase Support in Vitrified-Warmed Blastocyst Transfer","authors":"Jinlin Xie, Na Li, Haiyan Bai, Juanzi Shi, He Cai","doi":"10.1097/ogx.0000000000001196","DOIUrl":"https://doi.org/10.1097/ogx.0000000000001196","url":null,"abstract":"ABSTRACT The prevalence of obesity in reproductive age women continues to increase worldwide. Recent meta-analyses suggest that female obesity is negatively associated with live birth rate (LBR) after in vitro fertilization, as well as a higher risk of miscarriage after euploid embryo transfer. The interplay between adiposity and reproductive hormones such as progesterone may be partially responsible, and research shows that obese women may require higher progesterone supplementation in frozen-thawed embryo transfer (FET). Although the vaginal route of progesterone supplementation has predominated in most in vitro fertilization centers globally, the route of supplementation has been gaining interest. Studies comparing different routes have focused on the general infertility population, and it remains essential to investigate the interrelationship between the routes of progesterone supplementation, overweight/obesity, and treatment outcomes. This retrospective cohort study aimed to compare the difference in the LBR between vaginal progesterone and intramuscular progesterone in cryopreserved blastocyst transfer cycles and assess whether obesity may modify these associations. Patients who underwent a single, vitrified-warmed, blastocyst transfer between January 2018 and June 2021 and received exogenous hormone replacement for endometrial preparation were included. The route of progesterone supplementation was based on patient preference. The primary study outcome was live birth, and secondary outcomes included a positive b-hCG test result, clinical pregnancy, miscarriage, and total pregnancy loss. Normal weight was defined as 18.5–24.9 kg/m 2 , overweight was defined as a body mass index (BMI) of 25–29 kg/m 2 , and obese was defined as ≥30 kg/m 2 . Multivariate regression was used to assess the association between the route of progesterone supplementation and LBR while controlling for known potential covariates, and an interaction analysis was performed with overweight/obesity as the interaction term. A total of 6905 FET cycles from 6251 patients were included for this analysis, with 4616 cycles using vaginal progesterone and 2289 cycles using intramuscular progesterone. The proportions of overweight and obese women were comparable between the 2 groups. After adjusting for confounding variables, the LBR in the vaginal and intramuscular progesterone groups were 46.23% (2134/4616) and 48.62% (1113/2289), respectively (adjusted odds ratio [aOR], 0.89; 95% confidence interval [CI], 0.81–0.98). Although the rates of a positive serum hCG result and clinical pregnancy were similar between the 2 groups, miscarriage rate (15.34% vs 11.40%; aOR, 1.40; 95% CI, 1.20–1.63) and total pregnancy loss (22.22% vs 18.90%; aOR, 1.23; 95% CI, 1.08–1.40) per FET were significantly higher in the vaginal progesterone group than in the intramuscular progesterone group. Among normal-weight women, the LBR was lower in the vaginal progesterone group than the intramuscular prog","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/ogx.0000000000001192
Nicole Norby, Amanda B. Murchison, Shian McLeish, Taylor Ghahremani, Megan Whitham, Everett F. Magann
Importance Although not a common occurrence, uterine prolapse during pregnancy can have significant effects for pregnancy outcomes and quality of life of maternal patients. Most data about management exist as case reports; a review of these cases provides some guidance about treatment options. Objectives This review examines current literature about uterine prolapse during pregnancy to assess current information about this condition, prevalence, diagnosis, management, and outcomes. Evidence Acquisition Electronic databases (PubMed and Embase) were searched using terms “uterine prolapse” AND “pregnancy” AND “etiology” OR “risk factors” OR “diagnosis” OR “therapy” OR “management” limited to the English language and between the years 1980 and October 31, 2022. Results Upon review of 475 articles, 48 relevant articles were included as well as 6 relevant articles found on additional literature review for a total of 54 articles. Of those articles, 62 individual cases of uterine prolapse in pregnancy were reviewed including pregnancy complications, mode of delivery, and outcomes. Prevalence was noted to be rare, but much more common in second and subsequent pregnancies. Most diagnoses were made based on symptomatic prolapse on examination. Management strategies included bed rest, pessary use, and surgery (typically during the early second trimester). Complications included preterm delivery, patient discomfort, urinary retention, and urinary tract infection. Delivery methods included both cesarean and vaginal deliveries. Conclusions Although a rare condition, uterine prolapse in pregnancy is readily diagnosed on examination. Reasonable conservative management strategies include observation, attempted reduction of prolapse, and pessary use; if these measures fail, surgical treatment is an option. Relevance Our review compiles literature and known cases of uterine prolapse during pregnancy and current evidence about prevalence, diagnosis, management, outcomes, and complications of uterine prolapse during pregnancy in order to inform our target audience in their clinical practice. Target Audience Obstetricians and gynecologist, family physicians. Learning Objectives After completing this learning activity, the participant should be able to describe the prevalence of uterine prolapse during pregnancy, potential at-risk populations, and presenting symptoms; identify management strategies for uterine prolapse during pregnancy including both surgical and conservative approaches; and assess possible complications of uterine prolapse during pregnancy.
{"title":"Uterine Prolapse in Pregnancy: A Review","authors":"Nicole Norby, Amanda B. Murchison, Shian McLeish, Taylor Ghahremani, Megan Whitham, Everett F. Magann","doi":"10.1097/ogx.0000000000001192","DOIUrl":"https://doi.org/10.1097/ogx.0000000000001192","url":null,"abstract":"Importance Although not a common occurrence, uterine prolapse during pregnancy can have significant effects for pregnancy outcomes and quality of life of maternal patients. Most data about management exist as case reports; a review of these cases provides some guidance about treatment options. Objectives This review examines current literature about uterine prolapse during pregnancy to assess current information about this condition, prevalence, diagnosis, management, and outcomes. Evidence Acquisition Electronic databases (PubMed and Embase) were searched using terms “uterine prolapse” AND “pregnancy” AND “etiology” OR “risk factors” OR “diagnosis” OR “therapy” OR “management” limited to the English language and between the years 1980 and October 31, 2022. Results Upon review of 475 articles, 48 relevant articles were included as well as 6 relevant articles found on additional literature review for a total of 54 articles. Of those articles, 62 individual cases of uterine prolapse in pregnancy were reviewed including pregnancy complications, mode of delivery, and outcomes. Prevalence was noted to be rare, but much more common in second and subsequent pregnancies. Most diagnoses were made based on symptomatic prolapse on examination. Management strategies included bed rest, pessary use, and surgery (typically during the early second trimester). Complications included preterm delivery, patient discomfort, urinary retention, and urinary tract infection. Delivery methods included both cesarean and vaginal deliveries. Conclusions Although a rare condition, uterine prolapse in pregnancy is readily diagnosed on examination. Reasonable conservative management strategies include observation, attempted reduction of prolapse, and pessary use; if these measures fail, surgical treatment is an option. Relevance Our review compiles literature and known cases of uterine prolapse during pregnancy and current evidence about prevalence, diagnosis, management, outcomes, and complications of uterine prolapse during pregnancy in order to inform our target audience in their clinical practice. Target Audience Obstetricians and gynecologist, family physicians. Learning Objectives After completing this learning activity, the participant should be able to describe the prevalence of uterine prolapse during pregnancy, potential at-risk populations, and presenting symptoms; identify management strategies for uterine prolapse during pregnancy including both surgical and conservative approaches; and assess possible complications of uterine prolapse during pregnancy.","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/01.ogx.0000979672.75675.3d
Karen Borchert, Chelsea Thibodeau, Paige Varin, Heidi Wipf, Sarah Traxler, Christy M. Boraas
ABSTRACT Uncertain diagnosis can complicate the evaluation and treatment of patients presenting for undesired pregnancy termination at early gestational ages. Pregnant patients with no ultrasonography-identifiable pregnancy location receive classification of pregnancy of unknown location (PUL). Until receiving a definitive intrauterine pregnancy (IUP), ectopic pregnancy, or early pregnancy loss diagnosis, these patients are often managed expectantly with serial serum human chorionic gonadotropin (hCG) measurements and ultrasonography. Immediate treatment of undesired PUL with low-risk for ectopic pregnancy can be performed in ways that minimize the risk. This retrospective cohort study reviewed outcomes of pregnancies for PUL-diagnosed patients presenting at Planned Parenthood in Minnesota, North Dakota, and South Dakota to receive induced abortions between July 1, 2016, and December 31, 2019. Care of patients with PUL included assessment of health history, counseling, and ectopic pregnancy precaution reviews. Clinicians then proceeded to triage patients into low- and high-risk groups based on transvaginal ultrasonography findings and patient symptoms. For PUL patients deemed low risk for ectopic pregnancy, the choices of expectant management or induced abortion were given. Patients proceeding with induced abortions then proceeded with uterine aspiration or medication abortion. The primary objective compared the diagnosis of pregnancy location to time for 3 groups, which included the groups of patients choosing immediate treatment (via uterine aspiration or medical management), and the group of patients who initially chose expectant management (delay for diagnosis). Time to diagnosis, as measured in days, was recorded from initial PUL diagnosis until final pregnancy location diagnosis. A spontaneous decline of serum hCG after 48–72 hours in the delay-for-diagnosis group was recorded as a spontaneously resolved PUL consistent with spontaneous abortion. Incidence of ectopic pregnancies, complications such as transfusion-requiring hemorrhages, and failure to adhere with follow-up guidelines (greater than 60 days from PUL diagnosis without clinical contact and/or a pregnancy diagnosis) were also recorded. From a total of 19,151 abortion counters across the study period, 2.9% of patients (553) were diagnosed with PUL. High-risk diagnoses were given to 9.4% of patients (52), based on concerns from symptoms and ultrasounds (27 of these had ectopic pregnancies [51.9%]). Low-risk diagnoses were given to 90.6% of the remaining patients (501), who were given a choice of management. When compared with expectant management, results indicated that low-risk patients with undesired PUL experienced fewer days to diagnosis with immediate treatment by uterine aspiration (and a similar time frame to diagnosis with abortion via medication). For uterine aspiration, abortion treatment using simultaneous serial hCG trending was effective. Although this study lacked stat
{"title":"Medication Abortion and Uterine Aspiration for Undesired Pregnancy of Unknown Location: A Retrospective Cohort Study","authors":"Karen Borchert, Chelsea Thibodeau, Paige Varin, Heidi Wipf, Sarah Traxler, Christy M. Boraas","doi":"10.1097/01.ogx.0000979672.75675.3d","DOIUrl":"https://doi.org/10.1097/01.ogx.0000979672.75675.3d","url":null,"abstract":"ABSTRACT Uncertain diagnosis can complicate the evaluation and treatment of patients presenting for undesired pregnancy termination at early gestational ages. Pregnant patients with no ultrasonography-identifiable pregnancy location receive classification of pregnancy of unknown location (PUL). Until receiving a definitive intrauterine pregnancy (IUP), ectopic pregnancy, or early pregnancy loss diagnosis, these patients are often managed expectantly with serial serum human chorionic gonadotropin (hCG) measurements and ultrasonography. Immediate treatment of undesired PUL with low-risk for ectopic pregnancy can be performed in ways that minimize the risk. This retrospective cohort study reviewed outcomes of pregnancies for PUL-diagnosed patients presenting at Planned Parenthood in Minnesota, North Dakota, and South Dakota to receive induced abortions between July 1, 2016, and December 31, 2019. Care of patients with PUL included assessment of health history, counseling, and ectopic pregnancy precaution reviews. Clinicians then proceeded to triage patients into low- and high-risk groups based on transvaginal ultrasonography findings and patient symptoms. For PUL patients deemed low risk for ectopic pregnancy, the choices of expectant management or induced abortion were given. Patients proceeding with induced abortions then proceeded with uterine aspiration or medication abortion. The primary objective compared the diagnosis of pregnancy location to time for 3 groups, which included the groups of patients choosing immediate treatment (via uterine aspiration or medical management), and the group of patients who initially chose expectant management (delay for diagnosis). Time to diagnosis, as measured in days, was recorded from initial PUL diagnosis until final pregnancy location diagnosis. A spontaneous decline of serum hCG after 48–72 hours in the delay-for-diagnosis group was recorded as a spontaneously resolved PUL consistent with spontaneous abortion. Incidence of ectopic pregnancies, complications such as transfusion-requiring hemorrhages, and failure to adhere with follow-up guidelines (greater than 60 days from PUL diagnosis without clinical contact and/or a pregnancy diagnosis) were also recorded. From a total of 19,151 abortion counters across the study period, 2.9% of patients (553) were diagnosed with PUL. High-risk diagnoses were given to 9.4% of patients (52), based on concerns from symptoms and ultrasounds (27 of these had ectopic pregnancies [51.9%]). Low-risk diagnoses were given to 90.6% of the remaining patients (501), who were given a choice of management. When compared with expectant management, results indicated that low-risk patients with undesired PUL experienced fewer days to diagnosis with immediate treatment by uterine aspiration (and a similar time frame to diagnosis with abortion via medication). For uterine aspiration, abortion treatment using simultaneous serial hCG trending was effective. Although this study lacked stat","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/01.ogx.0000979656.52076.a2
Lola Loussert, Paul Berveiller, Alexia Magadoux, Michael Allouche, Christophe Vayssiere, Charles Garabedian, Paul Guerby
ABSTRACT Monitoring of fetal heart rate (FHR) is an important indicator of fetal well-being during labor, but it is subject to low specificity and interpretation variability; this causes the clinical effectiveness for preventing adverse outcomes to remain controversial. Fetal heart rate has inherent variability, but reduced or marked variability can reflect poor autonomic activity, indicating conditions such as fetal acidosis. Recent research has highlighted that marked variability can indicate fetal distress; more research is needed to validate and investigate this claim. This study aimed to understand the association between marked FHR variability during labor and subsequent neonatal acidosis. Data were collected from 2 French maternity units; inclusion criteria extended to women at 37 weeks' gestation or greater, with continuous FHR monitoring during labor. Exclusion criteria were intrauterine fetal death, medical termination, multiple pregnancies, noncephalic presentation, and cesarean delivery. The primary outcome for this study was neonatal acidosis, or an umbilical artery pH of less than or equal to 7.10. Secondary outcomes included severe acidosis (pH ≤7.0), a 5-minute Apgar score of less than 7, respiratory distress, neonatal intensive care unit admission, neonatal infection, and neonatal death. Final analysis included 4394 women who gave birth between January 1 and December 31, 2019. Of this population, 177 neonates experienced marked variability in FHR within 1 hour before delivery, with a median duration of marked variability of 2 minutes. Prevalence of neonatal acidosis was 15.3% in neonates who experienced marked FHR variability and 5.6% in those who did not (aRR, 2.30; 95% confidence interval [CI], 1.53–3.44). In addition, those with marked FHR variability more often experienced respiratory distress (aRR, 1.73; 95% CI, 1.15–2.58). Analysis was subsequently performed according to the National Institute of Child Health and Human Development category of FHR; the association between FHR variability and neonatal acidosis was significant in category I (aRR, 5.48; 95% CI, 1.88–15.96) and category II (aRR, 2.29; 95% CI, 1.40–3.74) groups. Category III FHR, however, had no significant association. Strengths of this study include the prospective cohort design, as well as generalizability. Subcategory assessment of the FHR patterns allowed for more accurate examination of the risk of neonatal acidosis. Limitations include an observational design and the strict exclusion criteria required to minimize bias, which reduces generalizability to low-risk groups. The findings of this study are consistent with previous literature in that FHR variability can be a significant marker for fetal outcomes. Clinically, these results can help providers recognize the risk of fetal and neonatal acidosis. Further research is needed to delineate further associations and assess interpretations of pattern variability.
{"title":"Association Between Marked Fetal Heart Rate Variability and Neonatal Acidosis: A Prospective Cohort Study","authors":"Lola Loussert, Paul Berveiller, Alexia Magadoux, Michael Allouche, Christophe Vayssiere, Charles Garabedian, Paul Guerby","doi":"10.1097/01.ogx.0000979656.52076.a2","DOIUrl":"https://doi.org/10.1097/01.ogx.0000979656.52076.a2","url":null,"abstract":"ABSTRACT Monitoring of fetal heart rate (FHR) is an important indicator of fetal well-being during labor, but it is subject to low specificity and interpretation variability; this causes the clinical effectiveness for preventing adverse outcomes to remain controversial. Fetal heart rate has inherent variability, but reduced or marked variability can reflect poor autonomic activity, indicating conditions such as fetal acidosis. Recent research has highlighted that marked variability can indicate fetal distress; more research is needed to validate and investigate this claim. This study aimed to understand the association between marked FHR variability during labor and subsequent neonatal acidosis. Data were collected from 2 French maternity units; inclusion criteria extended to women at 37 weeks' gestation or greater, with continuous FHR monitoring during labor. Exclusion criteria were intrauterine fetal death, medical termination, multiple pregnancies, noncephalic presentation, and cesarean delivery. The primary outcome for this study was neonatal acidosis, or an umbilical artery pH of less than or equal to 7.10. Secondary outcomes included severe acidosis (pH ≤7.0), a 5-minute Apgar score of less than 7, respiratory distress, neonatal intensive care unit admission, neonatal infection, and neonatal death. Final analysis included 4394 women who gave birth between January 1 and December 31, 2019. Of this population, 177 neonates experienced marked variability in FHR within 1 hour before delivery, with a median duration of marked variability of 2 minutes. Prevalence of neonatal acidosis was 15.3% in neonates who experienced marked FHR variability and 5.6% in those who did not (aRR, 2.30; 95% confidence interval [CI], 1.53–3.44). In addition, those with marked FHR variability more often experienced respiratory distress (aRR, 1.73; 95% CI, 1.15–2.58). Analysis was subsequently performed according to the National Institute of Child Health and Human Development category of FHR; the association between FHR variability and neonatal acidosis was significant in category I (aRR, 5.48; 95% CI, 1.88–15.96) and category II (aRR, 2.29; 95% CI, 1.40–3.74) groups. Category III FHR, however, had no significant association. Strengths of this study include the prospective cohort design, as well as generalizability. Subcategory assessment of the FHR patterns allowed for more accurate examination of the risk of neonatal acidosis. Limitations include an observational design and the strict exclusion criteria required to minimize bias, which reduces generalizability to low-risk groups. The findings of this study are consistent with previous literature in that FHR variability can be a significant marker for fetal outcomes. Clinically, these results can help providers recognize the risk of fetal and neonatal acidosis. Further research is needed to delineate further associations and assess interpretations of pattern variability.","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1097/ogx.0000000000001197
Ellen Kupka, Susanne Hesselman, Roxanne Hastie, Riccardo Lomartire, Anna Karin Wikström, Lina Bergman
ABSTRACT Evidence has shown that low-dose aspirin can reduce the risk of preeclampsia in women with risk factors; more recent evidence has shown that aspirin may also be useful for the prevention of spontaneous preterm birth, even among women without risk factors for preeclampsia. However, there are fewer studies examining the effectiveness of low-dose aspirin in this population, and the studies that have been done have generally been statistically underpowered. This study was meant to address this limitation in a large population of women who had previously experienced preterm birth, assessing whether low-dose aspirin treatment was associated with a lower risk for preterm birth. This study was a register-based cohort study performed using several different Swedish registries. The sample included all women with a first and second singleton birth between 2006 and 2019 and with a preterm birth in the first pregnancy. The primary outcome assessed was preterm birth during the second pregnancy, and secondary outcomes included assessment of preterm birth by severity (moderate preterm was between 32 and 36 weeks' gestation, and severe preterm was less than 32 weeks' gestation) and onset (spontaneous or medically indicated). The variable of interest was low-dose aspirin exposure or at least 1 dispensed prescription of 75 to 160 mg aspirin. The analysis included 22,127 women with a preterm birth in their first pregnancy followed by a second recorded pregnancy. Of this sample, 3057 (14%) were prescribed low-dose aspirin during their second pregnancy. Recurrent preterm birth occurred in 3703 individuals, of whom 547 (15%) had used low-dose aspirin. After adjusting for confounding variables, the incidence of preterm birth was lower in those using low-dose aspirin, with a marginal relative risk (mRR) of 0.87 (95% confidence interval [CI], 0.77–0.99). However, there was no difference in risk for moderate or severe preterm birth (moderate group: mRR, 0.90 [95% CI, 0.78–1.03]; severe group: mRR, 0.75 [95% CI, 0.54–1.04]). In adjusted analyses, there were no statistically significant differences for either medically indicated or spontaneous preterm birth between individuals who used low-dose aspirin and those who did not. The study was limited by its retrospective nature. In addition, the authors acknowledge that a dispensed prescription for aspirin does not necessarily equate to consistent intake of low-dose aspirin throughout a pregnancy. In addition, the population for this study was limited to those who had already experienced a preterm birth, which could affect the generalizability of the results. Although limited differences were found, a small protective effect could not be ruled out, and randomized controlled trials to understand more fully the effect low-dose aspirin might have on preterm birth would be helpful. Further research should also focus on whether the benefits of aspirin use during pregnancy outweigh the potential risks, as well as what the low
{"title":"Low-Dose Aspirin Use in Pregnancy and the Risk of Preterm Birth: A Swedish Register-Based Cohort Study","authors":"Ellen Kupka, Susanne Hesselman, Roxanne Hastie, Riccardo Lomartire, Anna Karin Wikström, Lina Bergman","doi":"10.1097/ogx.0000000000001197","DOIUrl":"https://doi.org/10.1097/ogx.0000000000001197","url":null,"abstract":"ABSTRACT Evidence has shown that low-dose aspirin can reduce the risk of preeclampsia in women with risk factors; more recent evidence has shown that aspirin may also be useful for the prevention of spontaneous preterm birth, even among women without risk factors for preeclampsia. However, there are fewer studies examining the effectiveness of low-dose aspirin in this population, and the studies that have been done have generally been statistically underpowered. This study was meant to address this limitation in a large population of women who had previously experienced preterm birth, assessing whether low-dose aspirin treatment was associated with a lower risk for preterm birth. This study was a register-based cohort study performed using several different Swedish registries. The sample included all women with a first and second singleton birth between 2006 and 2019 and with a preterm birth in the first pregnancy. The primary outcome assessed was preterm birth during the second pregnancy, and secondary outcomes included assessment of preterm birth by severity (moderate preterm was between 32 and 36 weeks' gestation, and severe preterm was less than 32 weeks' gestation) and onset (spontaneous or medically indicated). The variable of interest was low-dose aspirin exposure or at least 1 dispensed prescription of 75 to 160 mg aspirin. The analysis included 22,127 women with a preterm birth in their first pregnancy followed by a second recorded pregnancy. Of this sample, 3057 (14%) were prescribed low-dose aspirin during their second pregnancy. Recurrent preterm birth occurred in 3703 individuals, of whom 547 (15%) had used low-dose aspirin. After adjusting for confounding variables, the incidence of preterm birth was lower in those using low-dose aspirin, with a marginal relative risk (mRR) of 0.87 (95% confidence interval [CI], 0.77–0.99). However, there was no difference in risk for moderate or severe preterm birth (moderate group: mRR, 0.90 [95% CI, 0.78–1.03]; severe group: mRR, 0.75 [95% CI, 0.54–1.04]). In adjusted analyses, there were no statistically significant differences for either medically indicated or spontaneous preterm birth between individuals who used low-dose aspirin and those who did not. The study was limited by its retrospective nature. In addition, the authors acknowledge that a dispensed prescription for aspirin does not necessarily equate to consistent intake of low-dose aspirin throughout a pregnancy. In addition, the population for this study was limited to those who had already experienced a preterm birth, which could affect the generalizability of the results. Although limited differences were found, a small protective effect could not be ruled out, and randomized controlled trials to understand more fully the effect low-dose aspirin might have on preterm birth would be helpful. Further research should also focus on whether the benefits of aspirin use during pregnancy outweigh the potential risks, as well as what the low","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.1097/01.ogx.0000967008.55178.da
Maria W. Steenland, Amal N. Trivedi
ABSTRACT Approximately 1 in 8 individuals experience postpartum depression in the United States. Among them, 17% had their care covered by Medicaid and 10% had their care covered by a commercial payer. Postpartum depression is also more common among American Indian/Alaska Native (22%), Asian/Pacific Islander (19%), and Black (18%) individuals than White individuals (11%). Adverse postpartum health outcomes include reduced maternal quality of life, greater difficulty with social and partner relationships, increased odds of unemployment, and adverse child health outcomes. Effective treatments for postpartum depression include antidepressant medications and psychotherapy. Yet, these therapies are often underused, particularly among Medicaid enrollees and Black individuals, due to systemic racism and lack of access to health care, childcare, and transportation. One solution that has been suggested includes expanding Medicaid coverage to a year postpartum. One study in Oregon found that Medicaid expansion increased screening for and treatment of postpartum depression. The aim of this study was to compare the differences in treatment for postpartum depression among individuals whose births were covered by Medicaid versus commercial payers. This was a cohort study conducted in Arkansas with a difference-in-differences regression design. Data were collected from the state’s birth certificate records and all-payer claims database. Included were all births between January and June 2013, when Medicaid postpartum coverage ended 60 days after childbirth, and between January 2014 and December 2015, after the state expanded Medicaid postpartum coverage beyond 60 days if the individual’s income was below 138% of the federal poverty level. The primary outcomes were the filling of ≥1 antidepressant prescriptions and the number of days supplied in the first 60 days (early postpartum period) and 61 days to 6 months after childbirth (later postpartum period). The secondary outcomes were psychotherapy visits and a diagnosis of depression in the 6 months after childbirth. A total of 60,990 individuals gave birth in Arkansas between 2013 and 2015. Of these births, 71.7% were covered by Medicaid and 28.3% by commercial payers. Compared with individuals with commercially paid births, individuals who had a Medicaid-covered birth were younger (mean age, 25.5 vs 29.4 years), more likely to identify as Hispanic (10.8% vs 3.0%), and less likely to have a college or higher level of education (5.1% vs 55.5%). In the later postpartum period, 4.2% of those with Medicaid coverage filled a prescription for antidepressants before the expansion of Medicaid. In 2015, with Medicaid expansion, the likelihood of filling an antidepressant prescription in the later postpartum period increased by 110% (adjusted difference-in-differences, 4.6; 95% confidence interval [CI], 2.9–6.3). Similarly, in the early postpartum period, the likelihood of individuals with Medicaid filling an antidepressan
{"title":"Association of Medicaid Expansion With Postpartum Depression Treatment in Arkansas","authors":"Maria W. Steenland, Amal N. Trivedi","doi":"10.1097/01.ogx.0000967008.55178.da","DOIUrl":"https://doi.org/10.1097/01.ogx.0000967008.55178.da","url":null,"abstract":"ABSTRACT Approximately 1 in 8 individuals experience postpartum depression in the United States. Among them, 17% had their care covered by Medicaid and 10% had their care covered by a commercial payer. Postpartum depression is also more common among American Indian/Alaska Native (22%), Asian/Pacific Islander (19%), and Black (18%) individuals than White individuals (11%). Adverse postpartum health outcomes include reduced maternal quality of life, greater difficulty with social and partner relationships, increased odds of unemployment, and adverse child health outcomes. Effective treatments for postpartum depression include antidepressant medications and psychotherapy. Yet, these therapies are often underused, particularly among Medicaid enrollees and Black individuals, due to systemic racism and lack of access to health care, childcare, and transportation. One solution that has been suggested includes expanding Medicaid coverage to a year postpartum. One study in Oregon found that Medicaid expansion increased screening for and treatment of postpartum depression. The aim of this study was to compare the differences in treatment for postpartum depression among individuals whose births were covered by Medicaid versus commercial payers. This was a cohort study conducted in Arkansas with a difference-in-differences regression design. Data were collected from the state’s birth certificate records and all-payer claims database. Included were all births between January and June 2013, when Medicaid postpartum coverage ended 60 days after childbirth, and between January 2014 and December 2015, after the state expanded Medicaid postpartum coverage beyond 60 days if the individual’s income was below 138% of the federal poverty level. The primary outcomes were the filling of ≥1 antidepressant prescriptions and the number of days supplied in the first 60 days (early postpartum period) and 61 days to 6 months after childbirth (later postpartum period). The secondary outcomes were psychotherapy visits and a diagnosis of depression in the 6 months after childbirth. A total of 60,990 individuals gave birth in Arkansas between 2013 and 2015. Of these births, 71.7% were covered by Medicaid and 28.3% by commercial payers. Compared with individuals with commercially paid births, individuals who had a Medicaid-covered birth were younger (mean age, 25.5 vs 29.4 years), more likely to identify as Hispanic (10.8% vs 3.0%), and less likely to have a college or higher level of education (5.1% vs 55.5%). In the later postpartum period, 4.2% of those with Medicaid coverage filled a prescription for antidepressants before the expansion of Medicaid. In 2015, with Medicaid expansion, the likelihood of filling an antidepressant prescription in the later postpartum period increased by 110% (adjusted difference-in-differences, 4.6; 95% confidence interval [CI], 2.9–6.3). Similarly, in the early postpartum period, the likelihood of individuals with Medicaid filling an antidepressan","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136106146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.1097/ogx.0000000000001180
Rui Wang, Paul Tulikangas, Elisabeth C. Sappenfield
ABSTRACT After pelvic reconstructive surgery for pelvic organ prolapse, postoperative stress urinary incontinence (SUI) commonly occurs, which leads many women to choose to have a midurethral sling placed at the time of surgery, even in cases without symptomatic preoperative urinary incontinence. Approximately 27.3% of women with a sling had de novo SUI despite this intervention. Full evaluation of the societal and economic implications brought by a midurethral sling placement attempting to prevent postoperative de novo SUI at the time of a pelvic reconstructive surgery have yet to be evaluated. This study aimed to evaluate the 1-year cost-effectiveness of a midurethral sling in the prevention of SUI at the time of prolapse surgery. This assessment was a randomized controlled trial based on patient resource utilization and patient-reported effectiveness. Study data were obtained via the OPUS randomized clinical trial, which was performed through the Pelvic Floor Disorders Network (a cooperative agreement network sponsored through the National Institute of Child Health and Human Development). A total of 337 women with anterior vaginal prolapse and without SUI symptoms set to undergo treatment from May 2007 to January 2011 were included in the study. Patients were randomly assigned to receive either sham incisions or a midurethral sling during vaginal prolapse surgery. Follow-up occurred at 3, 6, and 12 months postsurgery, with surveys, physical examinations, and medical history. Cost data were collected, and overall health utility in quality-adjusted life-years (QALYs) was calculated. Secondary outcomes were urinary incontinence-specific quality of life and cases of urinary incontinence, as defined by bothersome incontinence symptoms and positive cough stress tests. Initial surgical procedures and subsequent urinary incontinence-related health care were all used for recording health care sector costs. Total costs for study participants were collected via health care resource utilization data, including office visits, additional surgical procedures, and related procedures. The incremental cost-effectiveness ratio was the difference between the sham incision and midurethral sling groups in mean cost, divided by difference in mean QALYs. Data for health care resource utilization were collected during the trial period. Questionnaires at baseline, 3, 6, 9, and 12 months were used to collect other costs. At 1 year, one-way sensitivity analysis was performed for assessing the varying effectiveness of midurethral slings at 1 year, by noting the urinary incontinence-associated patient costs and by using varied QALY for the sling group. Results were taken from a study population of 337 women who underwent randomization to be included in the analysis of cost-effectiveness. No great variance of characteristics existed between groups. One year after surgery, a lower rate of urinary incontinence existed for those in the midurethral sling group. Notably, QALYs w
{"title":"Cost Effectiveness of Concurrent Midurethral Sling at the Time of Prolapse Repair: Results From a Randomized Controlled Trial","authors":"Rui Wang, Paul Tulikangas, Elisabeth C. Sappenfield","doi":"10.1097/ogx.0000000000001180","DOIUrl":"https://doi.org/10.1097/ogx.0000000000001180","url":null,"abstract":"ABSTRACT After pelvic reconstructive surgery for pelvic organ prolapse, postoperative stress urinary incontinence (SUI) commonly occurs, which leads many women to choose to have a midurethral sling placed at the time of surgery, even in cases without symptomatic preoperative urinary incontinence. Approximately 27.3% of women with a sling had de novo SUI despite this intervention. Full evaluation of the societal and economic implications brought by a midurethral sling placement attempting to prevent postoperative de novo SUI at the time of a pelvic reconstructive surgery have yet to be evaluated. This study aimed to evaluate the 1-year cost-effectiveness of a midurethral sling in the prevention of SUI at the time of prolapse surgery. This assessment was a randomized controlled trial based on patient resource utilization and patient-reported effectiveness. Study data were obtained via the OPUS randomized clinical trial, which was performed through the Pelvic Floor Disorders Network (a cooperative agreement network sponsored through the National Institute of Child Health and Human Development). A total of 337 women with anterior vaginal prolapse and without SUI symptoms set to undergo treatment from May 2007 to January 2011 were included in the study. Patients were randomly assigned to receive either sham incisions or a midurethral sling during vaginal prolapse surgery. Follow-up occurred at 3, 6, and 12 months postsurgery, with surveys, physical examinations, and medical history. Cost data were collected, and overall health utility in quality-adjusted life-years (QALYs) was calculated. Secondary outcomes were urinary incontinence-specific quality of life and cases of urinary incontinence, as defined by bothersome incontinence symptoms and positive cough stress tests. Initial surgical procedures and subsequent urinary incontinence-related health care were all used for recording health care sector costs. Total costs for study participants were collected via health care resource utilization data, including office visits, additional surgical procedures, and related procedures. The incremental cost-effectiveness ratio was the difference between the sham incision and midurethral sling groups in mean cost, divided by difference in mean QALYs. Data for health care resource utilization were collected during the trial period. Questionnaires at baseline, 3, 6, 9, and 12 months were used to collect other costs. At 1 year, one-way sensitivity analysis was performed for assessing the varying effectiveness of midurethral slings at 1 year, by noting the urinary incontinence-associated patient costs and by using varied QALY for the sling group. Results were taken from a study population of 337 women who underwent randomization to be included in the analysis of cost-effectiveness. No great variance of characteristics existed between groups. One year after surgery, a lower rate of urinary incontinence existed for those in the midurethral sling group. Notably, QALYs w","PeriodicalId":19409,"journal":{"name":"Obstetrical & Gynecological Survey","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136107083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：